Ensuring  ||| S:0 E:9 ||| VBG
participant  ||| S:9 E:21 ||| NN
safety  ||| S:21 E:28 ||| NN
and  ||| S:28 E:32 ||| CC
trial  ||| S:32 E:38 ||| NN
integrity  ||| S:38 E:48 ||| NN
with  ||| S:48 E:53 ||| IN
clinical  ||| S:53 E:62 ||| JJ
trials  ||| S:62 E:69 ||| NNS
oversight  ||| S:69 E:79 ||| VBP
Clinical  ||| S:79 E:88 ||| JJ
trial  ||| S:88 E:94 ||| NN
oversight  ||| S:94 E:104 ||| NN
is  ||| S:104 E:107 ||| VBZ
a  ||| S:107 E:109 ||| DT
critical  ||| S:109 E:118 ||| JJ
element  ||| S:118 E:126 ||| NN
that  ||| S:126 E:131 ||| WDT
ensures  ||| S:131 E:139 ||| VBZ
the  ||| S:139 E:143 ||| DT
protection  ||| S:143 E:154 ||| NN
of  ||| S:154 E:157 ||| IN
research  ||| S:157 E:166 ||| NN
participants  ||| S:166 E:179 ||| NNS
and  ||| S:179 E:183 ||| CC
integrity  ||| S:183 E:193 ||| NN
of  ||| S:193 E:196 ||| IN
the  ||| S:196 E:200 ||| DT
data  ||| S:200 E:205 ||| NNS
collected ||| S:205 E:214 ||| VBN
.  ||| S:214 E:216 ||| .
The  ||| S:216 E:220 ||| DT
trial  ||| S:220 E:226 ||| NN
sponsor ||| S:226 E:233 ||| NN
,  ||| S:233 E:235 ||| ,
a  ||| S:235 E:237 ||| DT
local  ||| S:237 E:243 ||| JJ
Institutional  ||| S:243 E:257 ||| NNP
Review  ||| S:257 E:264 ||| NNP
Board ||| S:264 E:269 ||| NNP
,  ||| S:269 E:271 ||| ,
and  ||| S:271 E:275 ||| CC
independent  ||| S:275 E:287 ||| JJ
monitoring  ||| S:287 E:298 ||| NN
committees  ||| S:298 E:309 ||| NNS
all  ||| S:309 E:313 ||| RB
contribute  ||| S:313 E:324 ||| VB
with  ||| S:324 E:329 ||| IN
complementary  ||| S:329 E:343 ||| JJ
but  ||| S:343 E:347 ||| CC
overlapping  ||| S:347 E:359 ||| JJ
responsibilities ||| S:359 E:375 ||| NNS
.  ||| S:375 E:377 ||| .
Consistency  ||| S:377 E:389 ||| NNP
among  ||| S:389 E:395 ||| IN
these  ||| S:395 E:401 ||| DT
groups  ||| S:401 E:408 ||| NNS
is  ||| S:408 E:411 ||| VBZ
essential  ||| S:411 E:421 ||| JJ
for  ||| S:421 E:425 ||| IN
the  ||| S:425 E:429 ||| DT
smooth  ||| S:429 E:436 ||| JJ
conduct  ||| S:436 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
a  ||| S:447 E:449 ||| DT
clinical  ||| S:449 E:458 ||| JJ
trial  ||| S:458 E:464 ||| NN
but  ||| S:464 E:468 ||| CC
may  ||| S:468 E:472 ||| MD
be  ||| S:472 E:475 ||| VB
challenging  ||| S:475 E:487 ||| VBG
in  ||| S:487 E:490 ||| IN
resource-limited  ||| S:490 E:507 ||| JJ
settings  ||| S:507 E:516 ||| NNS
( ||| S:516 E:517 ||| -LRB-
RLS ||| S:517 E:520 ||| NNP
) ||| S:520 E:521 ||| -RRB-
.  ||| S:521 E:523 ||| .
Capacity  ||| S:523 E:532 ||| NN
building  ||| S:532 E:541 ||| NN
and  ||| S:541 E:545 ||| CC
training  ||| S:545 E:554 ||| NN
for  ||| S:554 E:558 ||| IN
RLS  ||| S:558 E:562 ||| NNP
may  ||| S:562 E:566 ||| MD
improve  ||| S:566 E:574 ||| VB
clinical  ||| S:574 E:583 ||| JJ
trials  ||| S:583 E:590 ||| NNS
oversight  ||| S:590 E:600 ||| NN
and  ||| S:600 E:604 ||| CC
ultimately  ||| S:604 E:615 ||| RB
medical  ||| S:615 E:623 ||| JJ
management ||| S:623 E:633 ||| NN
.  ||| S:633 E:635 ||| .
In  ||| S:635 E:638 ||| IN
this  ||| S:638 E:643 ||| DT
article ||| S:643 E:650 ||| NN
,  ||| S:650 E:652 ||| ,
we  ||| S:652 E:655 ||| PRP
review  ||| S:655 E:662 ||| VB
the  ||| S:662 E:666 ||| DT
components  ||| S:666 E:677 ||| NNS
necessary  ||| S:677 E:687 ||| JJ
for  ||| S:687 E:691 ||| IN
optimal  ||| S:691 E:699 ||| JJ
clinical  ||| S:699 E:708 ||| JJ
trial  ||| S:708 E:714 ||| NN
oversight  ||| S:714 E:724 ||| NN
and  ||| S:724 E:728 ||| CC
the  ||| S:728 E:732 ||| DT
issues  ||| S:732 E:739 ||| NNS
that  ||| S:739 E:744 ||| WDT
arise  ||| S:744 E:750 ||| VBP
in  ||| S:750 E:753 ||| IN
the  ||| S:753 E:757 ||| DT
RLS ||| S:757 E:760 ||| NNP
,  ||| S:760 E:762 ||| ,
with  ||| S:762 E:767 ||| IN
some  ||| S:767 E:772 ||| DT
suggested  ||| S:772 E:782 ||| JJ
strategies  ||| S:782 E:793 ||| NNS
for  ||| S:793 E:797 ||| IN
improvement ||| S:797 E:808 ||| NN
.  ||| S:808 E:810 ||| .
